Canaccord Genuity Reiterates a 'Buy' on Edwards Lifesciences (EW); Positive Final NCD
Tweet
Share
E-mailGet Alerts EW Hot Sheet
Price: $89.79 -0.04%
Rating Summary:
31 Buy, 14 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 6 | New: 26
Rating Summary:
31 Buy, 14 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 6 | New: 26
Join SI Premium – FREE
Canaccord Genuity reiterates a 'Buy' on Edwards Lifesciences (NYSE: EW) price target of $93.00.
Analyst, Jason R. Mills, said, "We think Medicare’s final NCD on TAVI is positive, as it allows for coverage of evidence development and coverage of non-inferiority trials. We recommend investors overweight EW relative to the mid/large-cap med-tech peer group owing to EW’s auspicious top-line growth prospects and exciting potential for significant operating leverage via TAVI uptake in the years to come...We remain comfortable with our recently-increased US SAPIEN revenue estimates for 2012 and 2013 of $208M (+500%) and $330M (+59%), respectively."
For an analyst ratings summary and ratings history on Edwards Lifesciences click here. For more ratings news on Edwards Lifesciences click here.
Shares of Edwards Lifesciences closed at $84.78 yesterday.
Analyst, Jason R. Mills, said, "We think Medicare’s final NCD on TAVI is positive, as it allows for coverage of evidence development and coverage of non-inferiority trials. We recommend investors overweight EW relative to the mid/large-cap med-tech peer group owing to EW’s auspicious top-line growth prospects and exciting potential for significant operating leverage via TAVI uptake in the years to come...We remain comfortable with our recently-increased US SAPIEN revenue estimates for 2012 and 2013 of $208M (+500%) and $330M (+59%), respectively."
For an analyst ratings summary and ratings history on Edwards Lifesciences click here. For more ratings news on Edwards Lifesciences click here.
Shares of Edwards Lifesciences closed at $84.78 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Emkay Global Starts Urban Company (URBANCO:IN) at Buy (1)
- Ferrovial SA (FER:SM) (FRRVF) Reiterated at Buy by UBS on Winning Bid For Tennessee Project
- ICICI Securities Resumes Dalmia Bharat Ltd (DALBHARA:IN) at Add (2)
Create E-mail Alert Related Categories
Analyst CommentsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
